Miller Fisher syndrome following COVID-19 vaccines: A scoping review

Jee Eun Kim, Byeol A. Yoon, Yoo Hwan Kim, Jong Kuk Kim, Jong Seok Bae

Research output: Contribution to journalArticlepeer-review

4 Scopus citations


Background and Purpose: Miller Fisher syndrome (MFS), a variant of Guillain–Barré Syndrome (GBS), could be underestimated in evaluations of its adverse events (AEs) following COVID-19 vaccination. We aimed to identify and characterize MFS following COVID-19 vaccination. Materials and Methods: Relevant studies reported on during the COVID-19 pandemic were identified in the MEDLINE, Embase, and other databases. Results: Nine cases of MFS following COVID-19 vaccination from various regions were included. Unlike MFS following COVID-19 infection, patients with MFS following COVID-19 vaccination frequently presented with anti-GQ1b antibody positivity (44%, 4/9). Unlike GBS following COVID-19 vaccination, only two of nine (22%) cases of MFS following COVID-19 vaccination had developed after viral-vector-related vaccine administration. Conclusions: Miller Fisher syndrome following COVID-19 vaccination seems to have a different pathophysiology from MFS following COVID-19 infection and GBS following COVID-19 vaccination. This neurological syndrome with a rare incidence and difficulty in diagnosis should be considered an AE of COVID-19 vaccination.

Original languageEnglish
Pages (from-to)604-609
Number of pages6
JournalActa Neurologica Scandinavica
Issue number5
StatePublished - Nov 2022

Bibliographical note

Funding Information:
This study was supported by grant no. 2020‐16 from the Kangdong Sacred Heart Hospital Fund (J. S. B.).

Publisher Copyright:
© 2022 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.


  • adverse effects
  • COVID-19 vaccine
  • Guillain–Barré syndrome
  • miller Fisher syndrome
  • systematic review


Dive into the research topics of 'Miller Fisher syndrome following COVID-19 vaccines: A scoping review'. Together they form a unique fingerprint.

Cite this